Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Vergnenègre · SciRah

Researcher profile · Semantic Scholar

A. Vergnenègre

Share profile

A. Vergnenègre — researcher profile on SciRah

h-index: 36
Works: 275
Citations: 14K

Most-cited papers

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
M. Hellmann, L. Paz-Ares, R. Bernabé Caro, B. Żurawski +22 more
2019New England Journal of Medicine2,293 citations Open access
Semantic Scholar
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
R. Herbst, G. Giaccone, F. de Marinis, N. Reinmuth +18 more
2020New England Journal of Medicine1,330 citations Open access
Semantic Scholar
Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study.
R. Corre, L. Greillier, H. Le Caer, C. Audigier-Valette +19 more
2016Journal of Clinical Oncology352 citations
Semantic Scholar
Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
N. Karachaliou, C. Mayo-de-las-Casas, C. Queralt, I. de Aguirre +26 more
2015JAMA Oncology250 citations Open access
Semantic Scholar
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small Cell Lung Cancer: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
L. Paz-Ares, S. Ramalingam, T. Ciuleanu, Jong-Seok Lee +35 more
2021Journal of Thoracic Oncology232 citations Open access
Semantic Scholar
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC
I. Chaib, N. Karachaliou, S. Pilotto, J. Codony-Servat +37 more
2017Journal of the National Cancer Institute188 citations Open access
Semantic Scholar
Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01).
C. Chouaid, C. Dujon, P. Dô, I. Monnet +14 more
2014Lung Cancer179 citations
Semantic Scholar
Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study.
J. L. Le Treut, M. Sault, H. Léna, P. Souquet +7 more
2013Annals of Oncology177 citations Open access
Semantic Scholar
Updated Overall Survival Analysis From IMpower110: Atezolizumab versus Platinum-Based Chemotherapy in Treatment-Naive PD-L1-Selected Non-Small Cell Lung Cancer.
J. Jassem, F. de Marinis, G. Giaccone, A. Vergnenègre +15 more
2021Journal of Thoracic Oncology165 citations Open access
Semantic Scholar
Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer
M. Molina-Vila, J. Bertran-Alamillo, A. Gascó, C. Mayo-de-las-Casas +12 more
2014Clinical Cancer Research151 citations Open access
Semantic Scholar
IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC
D. Spigel, F. Marinis, G. Giaccone, N. Reinmuth +16 more
2019Annals of Oncology140 citations Open access
Semantic Scholar
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
N. Baize, I. Monnet, L. Greillier, M. Geier +18 more
2020The Lancet Oncology133 citations Open access
Semantic Scholar
Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer
O. Bylicki, N. Paleiron, J. Margery, F. Guisier +5 more
2017Targeted oncology84 citations
Semantic Scholar
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
N. Karachaliou, J. Codony-Servat, C. Teixidó, S. Pilotto +30 more
2015Scientific Reports62 citations Open access
Semantic Scholar
Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers
M. Dusselier, E. Deluche, N. Delacourt, Julia Ballouhey +5 more
2019PLoS ONE42 citations Open access
Semantic Scholar
Clinical management patterns and treatment outcomes in patients with non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study
A. Carrato, A. Vergnenègre, M. Thomas, K. McBride +2 more
2014Current Medical Research and Opinion42 citations
Semantic Scholar
Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial.
G. Deplanque, R. Gervais, A. Vergnenègre, L. Falchero +7 more
2016Journal of American Academy of Dermatology40 citations
Semantic Scholar
ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation.
N. Karachaliou, A. Giménez-Capitán, A. Drozdowskyj, S. Viteri +8 more
2014Translational Lung Cancer Research40 citations
Semantic Scholar
Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in Outpatient Hospital and Hospital care at Home
M. Touati, L. Lamarsalle, S. Moreau, Françoise Vergnenègre +8 more
2016Supportive Care in Cancer36 citations Open access
Semantic Scholar
Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis
S. Peters, S. Ramalingam, L. Paz-Ares, R. B. Caro +16 more
2019Annals of Oncology34 citations Open access
Semantic Scholar
Cost‐Effectiveness Analysis of Afatinib versus Gefitinib for First‐Line Treatment of Advanced EGFR‐Mutated Advanced Non–Small Cell Lung Cancers
C. Chouaid, L. Luciani, K. Lelay, P. Dô +5 more
2017Journal of Thoracic Oncology34 citations Open access
Semantic Scholar
Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study.
J. Auliac, C. Chouaid, L. Greiller, Isabelle Monnet +12 more
2014Lung Cancer30 citations
Semantic Scholar
Randomized phase III study of nivolumab and ipilimumab versus carboplatin-based doublet in first-line treatment of PS 2 or elderly (≥ 70 years) patients with advanced non–small cell lung cancer (Energy-GFPC 06-2015 study).
H. Léna, I. Monnet, O. Bylicki, C. Audigier-Valette +12 more
2022Journal of Clinical Oncology28 citations
Semantic Scholar
Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer
L. Bonanno, C. Costa, M. Majem, J. Sánchez +10 more
2016BMC Cancer26 citations Open access
Semantic Scholar
Economic Analysis of First‐Line Treatment with Erlotinib in an EGFR‐Mutated Population with Advanced NSCLC
A. Vergnenègre, B. Massutí, F. de Marinis, E. Carcereny +6 more
2016Journal of Thoracic Oncology25 citations Open access
Semantic Scholar
Second-line treatments of small-cell lung cancers
N. Baize, I. Monnet, L. Greillier, G. Quéré +5 more
2017Expert Review of Anticancer Therapy22 citations
Semantic Scholar
Abstract CT221: Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment for patients with advanced non-small cell lung cancer (NSCLC) with brain metastases: Results from CheckMate 227
H. Borghaei, A. Płużański, R. B. Caro, M. Provencio +14 more
2020Tumor Biology19 citations
Semantic Scholar
Review of economic analyses of treatment for non-small–cell lung cancer (NSCLC)
A. Vergnenègre, C. Chouaïd
2018Expert review of pharmacoeconomics & outcomes research19 citations
Semantic Scholar
Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study
J. Auliac, Clément Fournier, C. Valette, M. Pérol +14 more
2016Targeted oncology19 citations
Semantic Scholar
Clinical management of molecular alterations identified by high throughput sequencing in patients with advanced solid tumors in treatment failure: Real-world data from a French hospital
Sandra Pinet, S. Durand, Alexandre Perani, Léa Darnaud +19 more
2023Frontiers in Oncology18 citations Open access
Semantic Scholar
Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505).
C. Chouaid, H. Le Caer, R. Corre, J. Crequit +6 more
2013Clinical Lung Cancer17 citations
Semantic Scholar
Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination for stage-IV non-small-cell lung cancer - VinMetAtezo trial, (GFPC‡ 04-2017).
A. Vergnenègre, I. Monnet, A. Bizieux, M. Bernardi +4 more
2020Future Oncology15 citations Open access
Semantic Scholar
First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers
T. Landré, Gaëtan Des Guetz, K. Chouahnia, C. Taleb +2 more
2019Journal of Cancer Research and Clinical Oncology15 citations Open access
Semantic Scholar
Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)
C. Raynaud, L. Greillier, J. Mazières, I. Monnet +13 more
2015BMC Cancer15 citations Open access
Semantic Scholar
Assessment of palliative care for advanced non-small-cell lung cancer in France: a prospective observational multicenter study (GFPC 0804 study).
A. Vergnenègre, S. Hominal, A. Tchalla, H. Bérard +11 more
2013Lung Cancer15 citations
Semantic Scholar
Association of PALB2 Messenger RNA Expression with Platinum‐Docetaxel Efficacy in Advanced Non–Small Cell Lung Cancer
N. Karachaliou, J. Bracht, M. Bruno, A. Drozdowskyj +14 more
2019Journal of Thoracic Oncology14 citations Open access
Semantic Scholar
A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective.
F. Barlesi, C. Chouaid, J. Crequit, H. Le Caer +9 more
2015Interactive Cardiovascular and Thoracic Surgery14 citations Open access
Semantic Scholar
Interim analysis of the Spanish Lung Cancer Group (SLCG) BRCA1-RAP80 Expression Customization (BREC) randomized phase III trial of customized therapy in advanced non-small cell lung cancer (NSCLC) patients (p) (NCT00617656/GECP-BREC).
T. Morán, M. Cobo, M. Dómine, M. Sánchez-Ronco +16 more
2013Journal of Clinical Oncology14 citations
Semantic Scholar
Patients with non-small-cell lung cancer harbouring a BRAF mutation: a multicentre study exploring clinical characteristics, management, and outcomes in a real-life setting: EXPLORE GFPC 02-14.
J. Auliac, S. Bayle, A. Vergnenègre, H. Le Caer +6 more
2018Current Oncology13 citations Open access
Semantic Scholar
Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo).
A. Vergnenègre, I. Monnet, C. Ricordel, A. Bizieux +11 more
2023Lung Cancer12 citations
Semantic Scholar
Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group.
H. Le Caer, I. Borget, R. Corre, C. Locher +10 more
2017Journal of Thoracic Disease12 citations Open access
Semantic Scholar
Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02–14 Study)
J. Auliac, I. Monnet, C. Dubos-Arvis, A. Chiappa +8 more
2017Targeted oncology12 citations
Semantic Scholar
FP13.03 IMpower110: Updated OS Analysis of Atezolizumab vs Platinum-Based Chemotherapy as First-Line Treatment in PD-L1–Selected NSCLC
R. Herbst, F. de Marinis, G. Giaccone, A. Vergnenègre +16 more
202111 citations Open access
Semantic Scholar
Two-Stage Bronchoscopic Endobronchial Valve Treatment Can Lead to Progressive Lung Volume Reduction and May Decrease Pneumothorax Risk
T. Egenod, J. Tricard, R. Fumat, Y. Simonneau +8 more
2021International Journal of COPD11 citations Open access
Semantic Scholar
Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small-cell lung cancers: An open phase II study using concurrent cisplatin-oral vinorelbine and radiotherapy (GFPC 08-06).
C. Locher, N. Pourel, H. Le Caer, H. Bérard +7 more
2018Lung Cancer11 citations
Semantic Scholar
Efficacy of Pemetrexed as Second-Line Therapy in Advanced NSCLC after Either Treatment-Free Interval or Maintenance Therapy with Gemcitabine or Erlotinib in IFCT-GFPC 05-02 Phase III Study
O. Bylicki, C. Ferlay, C. Chouaid, A. Lavolé +16 more
2013Journal of Thoracic Oncology11 citations Open access
Semantic Scholar
Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial.
F. de Marinis, A. Vergnenègre, A. Passaro, C. Dubos-Arvis +5 more
2015Future Oncology10 citations
Semantic Scholar
Economic analyses of immune-checkpoint inhibitors to treat lung cancer
A. Vergnenègre, C. Chouaid
2020Expert review of pharmacoeconomics & outcomes research9 citations
Semantic Scholar
LBA1 Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study
R. Herbst, F. de Marinis, G. Giaccone, N. Reinmuth +16 more
20199 citations Open access
Semantic Scholar
Oral vinorelbine-based concomitant chemoradiotherapy in unresectable stage III non-small cell lung cancer: a systematic review
P. Lesueur, I. Martel-Laffay, A. Escande, M. Kissel +5 more
2018Expert Review of Anticancer Therapy9 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

I. Monnet×15
Invite
I. Monnet — researcher profile on SciRah
C. Chouaid×14
Invite
C. Chouaid — researcher profile on SciRah
H. Le Caer×12
Invite
H. Le Caer — researcher profile on SciRah
J. Auliac×11
Invite
J. Auliac — researcher profile on SciRah

×10

Invite

F. de Marinis — researcher profile on SciRah

Invite

H. Bérard — researcher profile on SciRah

E. Carcereny×10

Invite

E. Carcereny — researcher profile on SciRah

Invite

B. Massutí — researcher profile on SciRah

Invite

R. Rosell — researcher profile on SciRah

Invite

R. Corre — researcher profile on SciRah

Invite

N. Baize — researcher profile on SciRah

Invite

L. Falchero — researcher profile on SciRah